Recent Updates
Recently added Catalysts
IONS Positive Sentiment

Diranersen demonstrates increasing clinical benefit at two years in early Alzheimer’s disease

Key Takeaway: Ionis Pharmaceuticals announced positive results from the Phase 2 CELIA study of diranersen, an investigational therapy for early Alzheimer's disease. Data presented at the CTAD 2026 conference showed that patients experienced increasing clinical benefits and a slowing of clinical decline over two years. This marks a significant advancement in treatment options for Alzheimer's.

Market Sentiment Analysis

POSITIVE FACTORS

  • Diranersen shows increasing clinical benefit over two years.
  • Results indicate slowing of clinical decline in early Alzheimer's.
  • Data presented at a significant Alzheimer's conference.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+3%
120-day peak, hindsight
Typical move
6.5%
average across 15 past catalysts
Cash runway
~31 mo
Minimal dilution risk
Lead asset
IONIS-FB-LRx
Phase 2 · Macular Degeneration

Full Press Release Details

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared new data from the Phase 2 CELIA study showing increasing clinical benefit of diranersen, an investigational antisense oligonucleotide (ASO) therapy targeting tau, in people living with early Alzheimer's disease at two years (Week 96). Results presented at the Clinical Trials on Alzheimer's Disease (CTAD) 2026 conference showed slowing of clinical decline across measures

Frequently Asked Questions

What is diranersen?

Diranersen is an investigational antisense oligonucleotide therapy targeting tau.

What were the results of the CELIA study?

The CELIA study showed increasing clinical benefits of diranersen over two years.

Where were the results presented?

Results were presented at the Clinical Trials on Alzheimer's Disease conference.

What does the study indicate about clinical decline?

The study indicates a slowing of clinical decline in early Alzheimer's patients.

Last updated: Nov 17, 2026